Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome

키워드

참고문헌 (190)

1. Talley NJ, "Epidemiology of colonic symptoms and the irritable bowel syndrome", Gastroenterology, 101, pp.927~934 (1991)
2. Jones R, "Irritable bowel syndrome in the general population", BMJ, 304, pp.87~90 (1992)
3. Drossman DA, "U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact", Dig Dis Sci, 38, pp.1569~1580 (1993)
4. Longstreth GF, "Functional bowel disorders", Gastroenterology, 130, pp.1480~1491 (2006)
5. Choung RS, "Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule", Am J Gastroenterol, 104, pp.1772~1779 (2009)
6. Baquero F, "The microbiome as a human organ", Clin Microbiol Infect, 18(4), pp.2~4 (2012)
7. Bäckhed F, "Host-bacterial mutualism in the human intestine", Science, 307, pp.1915~1920 (2005)
8. Qin J, "A human gut microbial gene catalogue established by metagenomic sequencing", Nature, 464, pp.59~65 (2010)
9. Burkholder PR, "Synthesis of vitamins by intestinal bacteria", Proc Natl Acad Sci U S A, 28, pp.285~289 (1942)
10. Bäckhed F, "The gut microbiota as an environmental factor that regulates fat storage", Proc Natl Acad Sci U S A, 101, pp.15718~15723 (2004)
11. Kamada N, "Control of pathogens and pathobionts by the gut microbiota", Nat Immunol, 14, pp.685~690 (2013)
12. Shi HN, "Bacterial colonization and the development of intestinal defences", Can J Gastroenterol, 18, pp.493~500 (2004)
13. Hammami R, "Anti-infective properties of bacteriocins: an update", Cell Mol Life Sci, 70, pp.2947~2967 (2013)
14. Schamberger GP, "Selection of recently isolated colicinogenic Escherichia coli strains inhibitory to Escherichia coli O157:H7", J Food Prot, 65, pp.1381~1387 (2002)
15. Cherrington CA, "Short-chain organic acids at ph 5.0 kill Escherichia coli and Salmonella spp. without causing membrane perturbation", J Appl Bacteriol, 70, pp.161~165 (1991)
16. Shin R, "Influence of intestinal anaerobes and organic acids on the growth of enterohaemorrhagic Escherichia coli O157:H7", J Med Microbiol, 51, pp.201~206 (2002)
17. Fischbach MA, "Eating for two: how metabolism establishes interspecies interactions in the gut", Cell Host Microbe, 10, pp.336~347 (2011)
18. Momose Y, "Competition for proline between indigenous Escherichia coli and E. coli O157:H7 in gnotobiotic mice associated with infant intestinal microbiota and its contribution to the colonization resistance against E. coli O157:H7", Antonie Van Leeuwenhoek, 94, pp.165~171 (2008)
19. Metchnikoff E, "The prolongation of life: optimistic studies" (1908), Putnam
20. Ringel Y, "Alterations in the intestinal microbiota and functional bowel symptoms", Gastrointest Endosc Clin N Am, 19, pp.141~150 (2009)
21. Simrén M, "Intestinal microbiota in functional bowel disorders: a Rome foundation report", Gut, 62, pp.159~176 (2013)
22. Turnbaugh PJ, "A core gut microbiome in obese and lean twins", Nature, 457, pp.480~484 (2009)
23. Turnbaugh PJ, "An obesity-associated gut microbiome with increased capacity for energy harvest", Nature, 444, pp.1027~1031 (2006)
24. Qin J, "A metagenome-wide association study of gut microbiota in type 2 diabetes", Nature, 490, pp.55~60 (2012)
25. Everard A, "Diabetes, obesity and gut microbiota", Best Pract Res Clin Gastroenterol, 27, pp.73~83 (2013)
26. D’Aversa F, "Gut microbiota and metabolic syndrome", Intern Emerg Med, 8(1), pp.S11~S15 (2013)
27. Karlsson FH, "Symptomatic atherosclerosis is associated with an altered gut metagenome", Nat Commun, 3, pp.1245~ (2012)
28. Manichanh C, "The gut microbiota in IBD", Nat Rev Gastroenterol Hepatol, 9, pp.599~608 (2012)
29. Bardhan PK, "Diagnosis of bacterial overgrowth after culturing proximal small-bowel aspirate obtained during routine upper gastrointestinal endoscopy", Scand J Gastroenterol, 27, pp.253~256 (1992)
30. Quigley EM, "Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics", Gastroenterology, 130, pp.S78~S90 (2006)
31. Posserud I, "Small intestinal bacterial overgrowth in patients with irritable bowel syndrome", Gut, 56, pp.802~808 (2007)
32. Bures J, "Small intestinal bacterial overgrowth syndrome", World J Gastroenterol, 16, pp.2978~2990 (2010)
33. Pimentel M, "Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome", Am J Gastroenterol, 95, pp.3503~3506 (2000)
34. Pimentel M, "Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study", Am J Gastroenterol, 98, pp.412~419 (2003)
35. Ford AC, "Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis", Clin Gastroenterol Hepatol, 7, pp.1279~1286 (2009)
36. Ghoshal UC, "Bugs and irritable bowel syndrome: the good, the bad and the ugly", J Gastroenterol Hepatol, 25, pp.244~251 (2010)
37. Simrén M, "Use and abuse of hydrogen breath tests", Gut, 55, pp.297~303 (2006)
38. Vanner S, "The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment", Gut, 57, pp.1315~1321 (2008)
39. Spiegel BM, "Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective", Clin Gastroenterol Hepatol, 9, pp.461~469 (2011)
40. DuPont AW, "Postinfectious irritable bowel syndrome", Clin Infect Dis, 46, pp.594~599 (2008)
41. Neish AS, "Microbes in gastrointestinal health and disease", Gastroenterology, 136, pp.65~80 (2009)
42. 이범재, "Irritable Bowel Syndrome, Gut Microbiota and Probiotics", Journal of Neurogastroenterology and Motility (JNM), 17(3), pp.252~266 (2011), 대한소화기 기능성질환∙운동학회
43. Rinttilä T, "Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects", Gut Pathog, 3, pp.6~ (2011)
44. Halvorson HA, "Riddle MS. Postinfectious irritable bowel syndrome: a meta-analysis", Am J Gastroenterol, 101, pp.1894~1899 (2006)
45. Thabane M, "Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome", Aliment Pharmacol Ther, 26, pp.535~544 (2007)
46. Schwille-Kiuntke J, "Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter", Neurogastroenterol Motil, 23, pp.e479~e488 (2011)
47. Spiller RC, "Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome", Gut, 47, pp.804~811 (2000)
48. Sasakawa C, "A new paradigm of bacteria-gut interplay brought through the study of Shigella", Proc Jpn Acad Ser B Phys Biol Sci, 86, pp.229~243 (2010)
49. Roxas JL, "Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner", Lab Invest, 90, pp.1152~1168 (2010)
50. Flynn AN, "Apoptosis-inducing factor contributes to epithelial cell apoptosis induced by enteropathogenic Escherichia coli", Can J Physiol Pharmacol, 89, pp.143~148 (2011)
51. Beatty JK, "Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection", World J Gastroenterol, 20, pp.3976~3985 (2014)
52. Ponnusamy K, "Microbial community and metabolomic comparison of irritable bowel syndrome faeces", J Med Microbiol, 60, pp.817~827 (2011)
53. Ohman L, "Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions", Nat Rev Gastroenterol Hepatol, 7, pp.163~173 (2010)
54. Ringel Y, "Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome", Am J Physiol Gastrointest Liver Physiol, 305, pp.G529~G541 (2013)
55. Karantanos T, "Current insights in to the pathophysiology of irritable bowel syndrome", Gut Pathog, 2, pp.3~ (2010)
56. Liebregts T, "Immune activation in patients with irritable bowel syndrome", Gastroenterology, 132, pp.913~920 (2007)
57. Weston AP, "Terminal ileal mucosal mast cells in irritable bowel syndrome", Dig Dis Sci, 38, pp.1590~1595 (1993)
58. O’Sullivan M, "Increased mast cells in the irritable bowel syndrome", Neurogastroenterol Motil, 12, pp.449~457 (2000)
59. Dunlop SP, "Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome", Am J Gastroenterol, 98, pp.1578~1583 (2003)
60. Spiller RC, "Overlap between irritable bowel syndrome and inflammatory bowel disease", Dig Dis, 27(1), pp.48~54 (2009)
61. Giovanni Barbara, "The Immune System in Irritable Bowel Syndrome", Journal of Neurogastroenterology and Motility (JNM), 17(4), pp.349~359 (2011), 대한소화기 기능성질환∙운동학회
62. Akbar A, "Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain", Gut, 57, pp.923~929 (2008)
63. Cremon C, "Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms", Am J Gastroenterol, 104, pp.392~400 (2009)
64. Guilarte M, "Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum", Gut, 56, pp.203~209 (2007)
65. Park JH, "Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome", J Gastroenterol Hepatol, 21, pp.71~78 (2006)
66. Wang SH, "Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome", World J Gastroenterol, 13, pp.6041~6047 (2007)
67. Barbara G, "Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome", Gastroenterology, 132, pp.26~37 (2007)
68. Braak B, "Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?", Am J Gastroenterol, 107, pp.715~726 (2012)
69. Cenac N, "Role for protease activity in visceral pain in irritable bowel syndrome", J Clin Invest, 117, pp.636~647 (2007)
70. Barbara G, "Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome", Gastroenterology, 126, pp.693~702 (2004)
71. Törnblom H, "Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome", Gastroenterology, 123, pp.1972~1979 (2002)
72. Round JL, "The gut microbiota shapes intestinal immune responses during health and disease", Nat Rev Immunol, 9, pp.313~323 (2009)
73. 김희선, "Increased Immunoendocrine Cells in Intestinal Mucosa of Postinfectious Irritable Bowel Syndrome Patients 3 Years after Acute Shigella Infection - An Observation in a Small Case Control Study", Yonsei Medical Journal, 51(1), pp.45~51 (2010), 연세대학교의과대학
74. Macsharry J, "Mucosal cytokine imbalance in irritable bowel syndrome", Scand J Gastroenterol, 43, pp.1467~1476 (2008)
75. Darkoh C, "Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome", PLoS One, 9, pp.e93144~ (2014)
76. Dinan TG, "Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?", Gastroenterology, 130, pp.304~311 (2006)
77. Oscar Rodríguez-Fandiño, "From Cytokines to Toll-Like Receptors and Beyond - Current Knowledge and Future Research Needs in Irritable Bowel Syndrome", Journal of Neurogastroenterology and Motility (JNM), 16(4), pp.363~373 (2010), 대한소화기 기능성질환∙운동학회
78. Scully P, "Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity", Am J Gastroenterol, 105, pp.2235~2243 (2010)
79. Chang L, "Serum and colonic mucosal immune markers in irritable bowel syndrome", Am J Gastroenterol, 107, pp.262~272 (2012)
80. McKernan DP, "Altered peripheral toll-like receptor responses in the irritable bowel syndrome", Aliment Pharmacol Ther, 33, pp.1045~1052 (2011)
81. Brint EK, "Differential expression of toll-like receptors in patients with irritable bowel syndrome", Am J Gastroenterol, 106, pp.329~336 (2011)
82. Belmonte L, "Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype", PLoS One, 7, pp.e42777~ (2012)
83. Ohman L, "levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?", Am J Gastroenterol, 107, pp.440~447 (2012)
84. Langhorst J, "Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome", Am J Gastroenterol, 104, pp.404~410 (2009)
85. Chadwick VS, "Activation of the mucosal immune system in irritable bowel syndrome", Gastroenterology, 122, pp.1778~1783 (2002)
86. Ohman L, "A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome", Clin Gastroenterol Hepatol, 3, pp.980~986 (2005)
87. Ohman L, "T-cell activation in patients with irritable bowel syndrome", Am J Gastroenterol, 104, pp.1205~1212 (2009)
88. Dunlop SP, "Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS", Gastroenterology, 125, pp.1651~1659 (2003)
89. Schoepfer AM, "Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients", Neurogastroenterol Motil, 20, pp.1110~1118 (2008)
90. Cremon C, "Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis", Expert Rev Gastroenterol Hepatol, 2, pp.735~740 (2008)
91. Ohman L, "B-cell activation in patients with irritable bowel syndrome (IBS)", Neurogastroenterol Motil, 21, pp.644~650 (2009)
92. Egen JG, "CTLA-4: new insights into its biological function and use in tumor immunotherapy", Nat Immunol, 3, pp.611~618 (2002)
93. Parkes GC, "Increases in ileal mast cells in patients with diarrhoea predominant irritable bowel syndrome may be due to a relative reduction in mucosa-associated Lactobacilli", Gut, 60(1), pp.A39~ (2011)
94. Löfmark S, "Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes", J Antimicrob Chemother, 58, pp.1160~1167 (2006)
95. Jernberg C, "Long-term ecological impacts of antibiotic administration on the human intestinal microbiota", ISME J, 1, pp.56~66 (2007)
96. De La Cochetière MF, "Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile", Microb Ecol, 56, pp.395~402 (2008)
97. Dethlefsen L, "The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing", PLoS Biol, 6, pp.e280~ (2008)
98. Parvez S, "Probiotics and their fermented food products are beneficial for health", J Appl Microbiol, 100, pp.1171~1185 (2006)
99. Wiström J, "Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study", J Antimicrob Chemother, 47, pp.43~50 (2001)
100. Mendall MA, "Antibiotic use, childhood affluence and irritable bowel syndrome (IBS)", Eur J Gastroenterol Hepatol, 10, pp.59~62 (1998)
101. Maxwell PR, "Antibiotics increase functional abdominal symptoms", Am J Gastroenterol, 97, pp.104~108 (2002)
102. De La Cochetière MF, "Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge", J Clin Microbiol, 43, pp.5588~5592 (2005)
103. Villarreal AA, "Use of broad-spectrum antibiotics and the development of irritable bowel syndrome", WMJ, 111, pp.17~20 (2012)
104. Pimentel M, "Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study", Dig Dis Sci, 51, pp.1297~1301 (2006)
105. Brandt LJ, "An evidence-based position statement on the management of irritable bowel syndrome", Am J Gastroenterol, 104(1), pp.S1~S35 (2009)
106. Pimentel M, "Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects", Dig Dis Sci, 56, pp.2067~2072 (2011)
107. Menees SB, "The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis", Am J Gastroenterol, 107, pp.28~35 (2012)
108. Gomes AM, "Bifidobacterium spp. and Lactobacillus acidophilus: biological, biochemical, technological and therapeutical properties relevant for use as probiotics", Trends Food Sci Technol, 10, pp.139~157 (1999)
109. Sinn DH, "Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome", Dig Dis Sci, 53, pp.2714~2718 (2008)
110. Kruis W, "A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome", Int J Colorectal Dis, 27, pp.467~474 (2012)
111. Sisson G, "Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome: a 12 week double-blind study", Aliment Pharmacol Ther, 40, pp.51~62 (2014)
112. Simrén M, "Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome--a randomized, double-blind, controlled study", Aliment Pharmacol Ther, 31, pp.218~227 (2010)
113. Ligaarden SC, "A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial", BMC Gastroenterol, 10, pp.16~ (2010)
114. Ludidi S, "Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients", Neurogastroenterol Motil, 26, pp.705~714 (2014)
115. Niv E, "The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study", Clin Nutr, 24, pp.925~931 (2005)
116. Guyonnet D, "Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial", Aliment Pharmacol Ther, 26, pp.475~486 (2007)
117. O’Sullivan MA, "Bacterial supplementation in the irritable bowel syndrome: a randomised double-blind placebo-controlled crossover study", Dig Liver Dis, 32, pp.294~301 (2000)
118. Chapman CM, "Health benefits of probiotics: are mixtures more effective than single strains?", Eur J Nutr, 50, pp.1~17 (2011)
119. Cash BD, "Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome", Curr Med Res Opin, 30, pp.1405~1415 (2014)
120. Hunter JO, "Controlled trial of oligofructose in the management of irritable bowel syndrome", J Nutr, 129, pp.1451S~1453S (1999)
121. Olesen M, "Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome", Am J Clin Nutr, 72, pp.1570~1575 (2000)
122. Paineau D, "The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders", Br J Nutr, 99, pp.311~318 (2008)
123. Silk DB, "Clinical trial:the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome", Aliment Pharmacol Ther, 29, pp.508~518 (2009)
124. Roberfroid M, "Prebiotic effects: metabolic and health benefits", Br J Nutr, 104(2), pp.S1~S63 (2010)
125. Halmos EP, "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome", Gastroenterology, 146, pp.67~75 (2014)
126. Simrén M, "Diet as a therapy for irritable bowel syndrome: progress at last", Gastroenterology, 146, pp.10~12 (2014)
127. Ley RE, "Microbial ecology: human gut microbes associated with obesity", Nature, 444, pp.1022~1023 (2006)
128. Duncan SH, "Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces", Appl Environ Microbiol, 73, pp.1073~1078 (2007)
129. Muegge BD, "Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans", Science, 332, pp.970~974 (2011)
130. Wu GD, "Linking long-term dietary patterns with gut microbial enterotypes", Science, 334, pp.105~108 (2011)
131. David LA, "Diet rapidly and reproducibly alters the human gut microbiome", Nature, 505, pp.559~563 (2014)
132. De Filippo C, "Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa", Proc Natl Acad Sci U S A, 107, pp.14691~14696 (2010)
133. Furnari M, "Reassessment of the role of methane production between irritable bowel syndrome and functional constipation", J Gastrointestin Liver Dis, 21, pp.157~163 (2012)
134. Staudacher HM, "Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome", J Hum Nutr Diet, 24, pp.487~495 (2011)
135. Staudacher HM, "Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome", J Nutr, 142, pp.1510~1518 (2012)
136. Shepherd SJ, "Short-chain carbohydrates and functional gastrointestinal disorders", Am J Gastroenterol, 108, pp.707~717 (2013)
137. Staudacher HM, "Mechanisms and efficacy of dietary FODMAP restriction in IBS", Nat Rev Gastroenterol Hepatol, 11, pp.256~266 (2014)
138. Codling C, "A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome", Dig Dis Sci, 55, pp.392~397 (2010)
139. Carroll IM, "Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome", Am J Physiol Gastrointest Liver Physiol, 301, pp.G799~G807 (2011)
140. Jeffery IB, "The microbiota link to irritable bowel syndrome: an emerging story", Gut Microbes, 3, pp.572~576 (2012)
141. Kassinen A, "The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects", Gastroenterology, 133, pp.24~33 (2007)
142. Jalanka-Tuovinen J, "Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome", Gut, 63, pp.1737~1745 (2014)
143. Krogius-Kurikka L, "Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers", BMC Gastroenterol, 9, pp.95~ (2009)
144. Durbán A, "Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome", FEMS Microbiol Ecol, 86, pp.581~589 (2013)
145. Jeffery IB, "An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota", Gut, 61, pp.997~1006 (2012)
146. Kerckhoffs AP, "Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome", J Med Microbiol, 60, pp.236~245 (2011)
147. Rappé MS, "The uncultured microbial majority", Annu Rev Microbiol, 57, pp.369~394 (2003)
148. Euzéby JP, "List of bacterial names with standing in nomenclature: a folder available on the Internet", Int J Syst Bacteriol, 47, pp.590~592 (1997)
149. Dethlefsen L, "An ecological and evolutionary perspective on human-microbe mutualism and disease", Nature, 449, pp.811~818 (2007)
150. Tap J, "Towards the human intestinal microbiota phylogenetic core", Environ Microbiol, 11, pp.2574~2584 (2009)
151. Manichanh C, "Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach", Gut, 55, pp.205~211 (2006)
152. Balsari A, "The fecal microbial population in the irritable bowel syndrome", Microbiologica, 5, pp.185~194 (1982)
153. Carroll IM, "Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome", Gut Pathog, 2, pp.19~ (2010)
154. Tana C, "Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome", Neurogastroenterol Motil, 22, pp.512~519 (2010)
155. Carroll IM, "Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome", Neurogastroenterol Motil, 24, pp.521~530 (2012)
156. Rigsbee L, "Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome", Am J Gastroenterol, 107, pp.1740~1751 (2012)
157. Mättö J, "Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome: a longitudinal study in IBS and control subjects", FEMS Immunol Med Microbiol, 43, pp.213~222 (2005)
158. Si JM, "Intestinal microecology and quality of life in irritable bowel syndrome patients", World J Gastroenterol, 10, pp.1802~1805 (2004)
159. Malinen E, "Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR", Am J Gastroenterol, 100, pp.373~382 (2005)
160. Kerckhoffs AP, "Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients", World J Gastroenterol, 15, pp.2887~2892 (2009)
161. Rajilić-Stojanović M, "Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome", Gastroenterology, 141, pp.1792~1801 (2011)
162. Wang H, "Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?", PLoS One, 9, pp.e90153~ (2014)
163. Parkes GC, "Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome", Neurogastroenterol Motil, 24, pp.31~39 (2012)
164. Maukonen J, "Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria", J Med Microbiol, 55, pp.625~633 (2006)
165. Saulnier DM, "Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome", Gastroenterology, 141, pp.1782~1791 (2011)
166. Leitch EC, "Selective colonization of insoluble substrates by human faecal bacteria", Environ Microbiol, 9, pp.667~679 (2007)
167. Lyra A, "Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification", World J Gastroenterol, 15, pp.5936~5945 (2009)
168. Duncan SH, "Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces", Int J Syst Evol Microbiol, 52, pp.1615~1620 (2002)
169. Barcenilla A, "Phylogenetic relationships of butyrate-producing bacteria from the human gut", Appl Environ Microbiol, 66, pp.1654~1661 (2000)
170. Hatayama H, "The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T", Biochem Biophys Res Commun, 356, pp.599~603 (2007)
171. Peng L, "Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier", Pediatr Res, 61, pp.37~41 (2007)
172. Załęski A, "Butyric acid in irritable bowel syndrome", Prz Gastroenterol, 8, pp.350~353 (2013)
173. Duboc H, "Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome", Neurogastroenterol Motil, 24, pp.513~520 (2012)
174. Chassard C, "Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome", Aliment Pharmacol Ther, 35, pp.828~838 (2012)
175. Lopez-Siles M, "Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes", Int J Med Microbiol, 304, pp.464~475 (2014)
176. Chen CC, "Probiotics and prebiotics: role in clinical disease states", Adv Pediatr, 52, pp.77~113 (2005)
177. Malinen E, "Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome", World J Gastroenterol, 16, pp.4532~4540 (2010)
178. Noor SO, "Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota", BMC Gastroenterol, 10, pp.134~ (2010)
179. Wexler HM, "Bacteroides: the good, the bad, and the nitty-gritty", Clin Microbiol Rev, 20, pp.593~621 (2007)
180. Moratalla A, "Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis", Liver Int, 34, pp.850~858 (2014)
181. Derrien M, "Mucin-bacterial interactions in the human oral cavity and digestive tract", Gut Microbes, 1, pp.254~268 (2010)
182. King TS, "Abnormal colonic fermentation in irritable bowel syndrome", Lancet, 352, pp.1187~1189 (1998)
183. Pimentel M, "Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity", Am J Physiol Gastrointest Liver Physiol, 290, pp.G1089~G1095 (2006)
184. Pimentel M, "Methane production during lactulose breath test is associated with gastrointestinal disease presentation", Dig Dis Sci, 48, pp.86~92 (2003)
185. Chatterjee S, "The degree of breath methane production in IBS correlates with the severity of constipation", Am J Gastroenterol, 102, pp.837~841 (2007)
186. Kim G, "Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath", Dig Dis Sci, 57, pp.3213~3218 (2012)
187. Rana SV, "Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from North India", Dig Dis Sci, 54, pp.132~135 (2009)
188. Durbán A, "Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome", Environ Microbiol Rep, 4, pp.242~247 (2012)
189. Crouzet L, "The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota", Neurogastroenterol Motil, 25, pp.e272~e282 (2013)
190. Swidsinski A, "Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease", J Clin Microbiol, 43, pp.3380~3389 (2005)

관련 논문AI추천